Microfluidic Encapsulation of Genetically Engineered Bone‐marrow‐derived Mesenchymal Stem Cells for Bone Defect Healing
Advanced Healthcare Materials · 2026-05 · 15 (20)
DOI: 10.1002/adhm.202505260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 15.03.2026. Verfasst von Wanchuan Ding und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, School of Biological Science and Medical Engineering, Nanjing Drum Tower Hospital, Southeast University, N…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Bone Marrow Cells, Genetic Engineering, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Key Research & Development Program of Jiangsu Province.
Abstract (Originalsprache)
Mesenchymal stem cells (MSCs) hold significant potential for bone healing. Current efforts focus on enhancing stem cell viability and differentiation potential to improve therapeutic outcomes. Here, we transfected bone MSCs (BMSCs) with RUNX2 plasmid nanoparticles (BMSCs pRUNX2 ) and encapsulated them into gelatin methacryloyl (GelMA) hydrogel microcarriers (BRGMs) for bone regeneration. As the BRGMs were generated from microfluidics, they possess uniform sizes and good injectability to fit the complex shapes of clinical bone defects. In addition, they can maintain the high cell viability and further osteogenic induction capacity of loaded engineered BMSCs pRUNX2 . Moreover, enhanced osteogenic differentiation of them in vitro was also proved by the detection of osteogenic differentiation genes and proteins expression, staining of alkaline phosphatase, and alizarin red. Based on these features, we have demonstrated satisfactory bone regeneration in situ when the BRGMs were added into 5 mm full‐thickness rat calvarial defects for 8 weeks. Therefore, we believed that the proposed microfluidic encapsulation of genetically engineered BMSCs platform is a promising candidate for bone defect healing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, School of Biological Science and Medical Engineering, Nanjing Drum Tower Hospital, Southeast University, Nanjing, China.
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, China.
- Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing, China.
ORCID-Profile: Yuanjin Zhao
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Key Research & Development Program of Jiangsu Province
- Joint Fund of Henan Province Science and Technology R&D Program
- Clinical Trials from Nanjing Drum Tower Hospital
- The research funding of Yangtze River Pharmaceutical Group
Zitieren
APA
Ding, W., Luo, Z., Che, J., Gan, J., & Zhao, Y. (2026). Microfluidic Encapsulation of Genetically Engineered Bone‐marrow‐derived Mesenchymal Stem Cells for Bone Defect Healing. Advanced Healthcare Materials, 15(20). https://doi.org/10.1002/adhm.202505260
Vancouver
Ding W, Luo Z, Che J, Gan J, Zhao Y. Microfluidic Encapsulation of Genetically Engineered Bone‐marrow‐derived Mesenchymal Stem Cells for Bone Defect Healing. Advanced Healthcare Materials. 2026;15(20). doi:10.1002/adhm.202505260
BibTeX
@article{Ding2026,
author = {Ding, Wanchuan and Luo, Zhiqiang and Che, Junyi and Gan, Jingjing and Zhao, Yuanjin},
title = {Microfluidic Encapsulation of Genetically Engineered Bone‐marrow‐derived Mesenchymal Stem Cells for Bone Defect Healing},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {20},
doi = {10.1002/adhm.202505260}
}
EUVIMED